Allegra Hives is a drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is protected by 16 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 14, 2017. Details of Allegra Hives's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US6037353 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep, 2017
(7 years ago) |
Expired
|
| US6037353 | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar, 2017
(7 years ago) |
Expired
|
|
US5932247 (Pediatric) | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(9 years ago) |
Expired
|
|
US5855912 (Pediatric) | Pharmaceutical compositions for piperidinalkanol compounds |
Aug, 2015
(9 years ago) |
Expired
|
|
US6113942 (Pediatric) | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(9 years ago) |
Expired
|
| US5932247 | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) |
Expired
|
| US6113942 | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) |
Expired
|
| US5855912 | Pharmaceutical compositions for piperidinalkanol compounds |
Feb, 2015
(9 years ago) |
Expired
|
|
US7135571 (Pediatric) | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(10 years ago) |
Expired
|
|
US7138524 (Pediatric) | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(10 years ago) |
Expired
|
|
US5578610 (Pediatric) | Piperidine derivatives |
May, 2014
(10 years ago) |
Expired
|
| US7135571 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(10 years ago) |
Expired
|
| US7138524 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(10 years ago) |
Expired
|
| US5578610 | Piperidine derivatives |
Nov, 2013
(10 years ago) |
Expired
|
|
US6399632 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(12 years ago) |
Expired
|
|
US6187791 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(12 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Allegra Hives's patents.
Latest Legal Activities on Allegra Hives's Patents
Given below is the list of recent legal activities going on the following patents of Allegra Hives.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 17 Dec, 2018 | US7135571 |
| Maintenance Fee Reminder Mailed Critical | 25 Jun, 2018 | US7135571 |
| Expire Patent Critical | 19 Dec, 2014 | US7138524 |
| Petition Decision - Granted Critical | 31 Jan, 2008 | US7135571 |
| Mail-Petition Decision - Granted | 31 Jan, 2008 | US7135571 |
| Petition Entered | 14 Jan, 2008 | US7135571 |
| Post Issue Communication - Certificate of Correction | 05 Jan, 2007 | US7135571 |
| Patent Issue Date Used in PTA Calculation Critical | 21 Nov, 2006 | US7138524 |
| Recordation of Patent Grant Mailed Critical | 21 Nov, 2006 | US7138524 |
| Patent Issue Date Used in PTA Calculation Critical | 14 Nov, 2006 | US7135571 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Allegra Hives and ongoing litigations to help you estimate the early arrival of Allegra Hives generic.
Allegra Hives's Litigations
Allegra Hives been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 02, 1999, against patent number US6037353. The petitioner , challenged the validity of this patent, with YOUNG as the respondent. Click below to track the latest information on how companies are challenging Allegra Hives's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6037353 | November, 1999 |
Decision
(02 Nov, 1999) | YOUNG | |
US patents provide insights into the exclusivity only within the United States, but Allegra Hives is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Allegra Hives's family patents as well as insights into ongoing legal events on those patents.
Allegra Hives's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Allegra Hives's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 14, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Allegra Hives Generic API suppliers:
Fexofenadine Hydrochloride is the generic name for the brand Allegra Hives. 14 different companies have already filed for the generic of Allegra Hives, with Dr Reddys Labs Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Allegra Hives's generic
How can I launch a generic of Allegra Hives before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Allegra Hives's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Allegra Hives's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Allegra Hives -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 30 mg, 60 mg and 180 mg |
Alternative Brands for Allegra Hives
Allegra Hives which is used for relieving symptoms of respiratory allergies and hives in adults and children., has several other brand drugs in the same treatment category and using the same active ingredient (Fexofenadine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||
|---|---|---|---|---|---|---|---|---|
| Chattem Sanofi |
| |||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Fexofenadine Hydrochloride. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Chattem Sanofi |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Fexofenadine Hydrochloride, Allegra Hives's active ingredient. Check the complete list of approved generic manufacturers for Allegra Hives
About Allegra Hives
Allegra Hives is a drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is used for relieving symptoms of respiratory allergies and hives in adults and children. Allegra Hives uses Fexofenadine Hydrochloride as an active ingredient. Allegra Hives was launched by Chattem Sanofi in 2011.
Approval Date:
Allegra Hives was approved by FDA for market use on 24 January, 2011.
Active Ingredient:
Allegra Hives uses Fexofenadine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Fexofenadine Hydrochloride ingredient
Treatment:
Allegra Hives is used for relieving symptoms of respiratory allergies and hives in adults and children.
Dosage:
Allegra Hives is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 60MG | TABLET | Discontinued | ORAL |
| 180MG | TABLET | Over the counter | ORAL |